Deerfield

Total investments

177

Average round size

68M

Portfolio companies

148

Rounds per year

5.90

Lead investments

39

Follow on index

0.16

Exits

76

Stages of investment
Early Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Deerfield is the famous VC, which was founded in 1994. The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the New York.

Besides them, we counted 15 critical employees of this fund in our database.

The higher amount of exits for fund were in 2015. When the investment is from Deerfield the average startup value is 500 millions - 1 billion dollars. The fund is constantly included in 2-6 investment rounds annually. The common things for fund are deals in the range of 50 - 100 millions dollars. Comparing to the other companies, this Deerfield performs on 20 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 26 percentage points more often commits exit comparing to other organizations. The high activity for fund was in 2015. Despite it in 2019 the fund had an activity.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Deerfield, startups are often financed by New Enterprise Associates, Third Rock Ventures, OrbiMed. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, OrbiMed, T. Rowe Price. In the next rounds fund is usually obtained by Deerfield Capital Management, OrbiMed, Venrock.

Among the most successful fund investment fields, there are Biopharma, Medical. The fund has no exact preference in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Among the most popular portfolio startups of the fund, we may highlight AveXis, TESARO, Spark Therapeutics. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

Show more

Investments analytics

Analytics

Total investments
177
Lead investments
39
Exits
76
Rounds per year
5.90
Follow on index
0.16
Investments by industry
  • Health Care (109)
  • Biotechnology (106)
  • Medical (67)
  • Pharmaceutical (49)
  • Therapeutics (40)
  • Show 60 more
Investments by region
  • United States (147)
  • Ireland (2)
  • Israel (5)
  • Bermuda (1)
  • Italy (2)
  • Show 6 more
Peak activity year
2015
Number of Unicorns
6
Number of Decacorns
6
Number of Minotaurs
6

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
132M
Group Appearance index
0.69
Avg. company exit year
10
Avg. multiplicator
1.80
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Innervace 08 Sep 2022 Health Care, Medical, Neuroscience Early Stage Venture 40M United States, Pennsylvania, Philadelphia
Vesta Healthcare 06 Apr 2021 Elder and Disabled Care, Outcome Management (Healthcare), Information Technology, Health Care, Home Health Care, Elder Care Late Stage Venture 65M United States, New York, New York

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.